Adicet Bio Appoints Stewart Abbot Chief Scientific Officer

Xconomy San Francisco — 

Stewart Abbot has been appointed chief scientific officer of Adicet Bio. Before coming to the Menlo Park, CA-based company, Abbot was chief development officer at Fate Therapeutics (NASDAQ: FATE) in La Jolla, CA. Adicet launched in 2016 backed by a $51 million Series A round of financing to develop “off-the-shelf” immune cell therapies for cancer and other diseases.